Zai Lab Limited - ADR

NASDAQ:ZLAB   3:59:59 PM EDT
105.18
+1.18 (+1.14%)
4:02:45 PM EDT: $105.23 +0.05 (+0.05%)
Products

Zai Lab Partner Macrogenics Announces FDA Approval Of Margenza™ For Patients With Pretreated Metastatic Her2-Positive Breast Cancer

Published: 12/17/2020 01:23 GMT
Zai Lab Limited - ADR (ZLAB) - Zai Lab Partner Macrogenics Announces FDA Approval of Margenza™ for Patients With Pretreated Metastatic Her2-positive Breast Cancer.
Product Launch in U.S. Anticipated in March 2021.